down arrow

BioVie, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09074F2074
USD
1.61
0.14 (9.52%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.561.70

52 Week

1.2530.90
Valuation
Technical
Day's Volume

CASH

128.91 k

Shareholding (Mar 2025)

FII

0.40%

Held by 18 FIIs

DII

95.67%

Held by 4 DIIs

Promoter

0.00%

How big is BioVie, Inc.?

22-Jun-2025

As of Jun 18, BioVie, Inc. has a market capitalization of 19.13 million and reported net sales of 0.00 million with a net profit of -18.99 million for the latest four quarters. The company has shareholder's funds of 15.51 million and total assets of 25.21 million as of Jun'24.

Market Cap: As of Jun 18, BioVie, Inc. has a market capitalization of 19.13 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in Mar'25, Dec'24, Sep'24, and Jun'24, BioVie, Inc. reported net sales of 0.00 million and a net profit of -18.99 million.<BR><BR>Balance Sheet Snapshot: As of Jun'24, the company reported shareholder's funds of 15.51 million and total assets of 25.21 million.

Read More

What does BioVie, Inc. do?

22-Jun-2025

BioVie, Inc. is a clinical-stage pharmaceutical company focused on developing drug therapies for liver disease. As of March 2025, it has a market cap of $19.13 million and reported a net profit loss of $3 million.

Overview:<BR>BioVie, Inc. is a clinical-stage company in the Pharmaceuticals & Biotechnology industry, focused on the discovery, development, and commercialization of drug therapies for liver disease.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 19.13 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.06 <BR>Return on Equity: -87.15% <BR>Price to Book: 0.88<BR><BR>Contact Details:<BR>Address: 2120 Colorado Ave Ste 230, SANTA MONICA CA: 90404-3559 <BR>Tel: 1 310 4444300 <BR>Website: http://www.biovieinc.com/

Read More

Who are in the management team of BioVie, Inc.?

22-Jun-2025

As of March 2022, the management team of BioVie, Inc. is led by CEO and Director Mr. Terren Peizer, with the Board of Directors including Mr. Richard Berman, Mr. Steven Gorlin, Dr. Robert Hariri, Mr. Rajah Menon, and Mr. Sigmund Rogich.

As of March 2022, the management team of BioVie, Inc. includes Mr. Terren Peizer, who serves as the Chief Executive Officer and Director. Additionally, the Board of Directors comprises Mr. Richard Berman, Mr. Steven Gorlin, Dr. Robert Hariri, Mr. Rajah Menon, and Mr. Sigmund Rogich, all of whom hold the designation of Director.

Read More

Is BioVie, Inc. technically bullish or bearish?

20-Sep-2025

As of July 31, 2025, BioVie, Inc. shows a mildly bullish trend overall, despite mixed signals from various indicators and a significant year-to-date underperformance of -90.65% compared to the S&P 500's 12.22%.

As of 31 July 2025, the technical trend for BioVie, Inc. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The Bollinger Bands are mildly bearish on both weekly and monthly time frames, and the daily moving averages are bearish. The KST shows a bearish stance weekly but is mildly bullish monthly. The OBV is mildly bullish weekly, but there is no trend on the monthly scale. Overall, the indicators suggest a mildly bullish stance, but the bearish signals in the weekly MACD and daily moving averages temper this outlook.<BR><BR>In terms of performance, BioVie has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -90.65% versus the S&P 500's 12.22%, highlighting a stark contrast in performance.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 14 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.92

stock-summary
Return on Equity

-92.29%

stock-summary
Price to Book

0.71

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.59%
0%
-3.59%
6 Months
-85.5%
0%
-85.5%
1 Year
-94.74%
0%
-94.74%
2 Years
-99.04%
0%
-99.04%
3 Years
-70.67%
0%
-70.67%
4 Years
-99.7%
0%
-99.7%
5 Years
-99.82%
0%
-99.82%

BioVie, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is BioVie, Inc. technically bullish or bearish?

As of 31 July 2025, the technical trend for BioVie, Inc. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The Bollinger Bands are mildly bearish on both weekly and monthly time frames, and the daily moving averages are bearish. The KST shows a bearish stance weekly but is mildly bullish monthly. The OBV is mildly bullish weekly, but there is no trend on the monthly scale. Overall, the indicators suggest a mildly bullish stance, but the bearish signals in the weekly MACD and daily moving averages temper this outlook. In terms of performance, BioVie has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -90.65% versus the S&P 500's 12.22%, highlighting a stark contrast in performance....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-236.38%
EBIT to Interest (avg)
-33.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.06
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.73%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.92
EV to EBIT
0.16
EV to EBITDA
0.16
EV to Capital Employed
2.39
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1519.24%
ROE (Latest)
-87.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 11 Schemes (3.93%)

Foreign Institutions

Held by 18 Foreign Institutions (0.4%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 28.57% vs 46.15% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-4.70",
          "chgp": "23.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.50",
          "val2": "-4.90",
          "chgp": "28.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is 45.48% vs 36.18% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.80",
          "val2": "-32.00",
          "chgp": "44.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "2.90",
          "chgp": "-89.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "1.80",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.50",
          "val2": "-32.10",
          "chgp": "45.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.60
-4.70
23.40%
Interest
0.00
0.40
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.50
-4.90
28.57%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 28.57% vs 46.15% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jun'25stock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-17.80
-32.00
44.38%
Interest
0.30
2.90
-89.66%
Exceptional Items
0.00
1.80
-100.00%
Consolidate Net Profit
-17.50
-32.10
45.48%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2025 is 45.48% vs 36.18% in Jun 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About BioVie, Inc. stock-summary
stock-summary
BioVie, Inc.
Pharmaceuticals & Biotechnology
BioVie Inc clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company has developed a new drug candidate, BIV201 (continuous infusion terlipressin) and has completed a mid-stage Phase IIa clinical trial for treating ascites due to advanced liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The initial target for BIV201 therapy is refractory ascites, a serious complication of liver cirrhosis with an estimated 50% mortality rate within six to 12 months.
Company Coordinates stock-summary
Company Details
2120 Colorado Ave Ste 230 , SANTA MONICA CA : 90404-3559
stock-summary
Tel: 1 310 4444300
stock-summary
http://www.biovieinc.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."